Surgical treatment of recurrent cervical cancer: State of the art and new achievements

Long‐term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies

“…Better understandings of the surgical indications and the great advance in operative techniques have played a crucial role. Promising overall survival rates are reported, which are indeed ameliorating in comparison to historic collectives [19]. Marnitz et al [20] in an attempt to describe the differences concerning indications and contraindications, preoperative staging, and adjuvant therapy for pelvic exenteration centers in Germany and the United States, emphasizes the fact that individual experience and mentality play an additional significant role in the decision-making process in advanced cancer situations.…”

Reirradiation Using High-Dose-Rate Interstitial Brachytherapy for Locally Recurrent Cervical Cancer: A Single Institutional Experience

“…1 Surgical salvage involving anterior, posterior, or total pelvic exenteration, which can only be offered to a very selected group of patients with central pelvic recurrence, has demonstrated favorable treatment outcomes, with the 5-year survival rate ranging from 30% to 60%. 2 Moreover, laterally extended endopelvic resection has also been proposed for pelvic sidewall recurrence. 3 However, even in patients with seemingly resectable lesions, surgery is technically challenging because of the difficulties of operating in previously irradiated, manipulated tissue.…”

Dubens Eksenteracinės Operacijos – Ultraradikalios Operacijos Klaipėdos Universitetinėje Ligoninėje

“…5 metų išgyvenamumas siekia nuo 20 iki 42% [20]. Laikui bėgant mirštamumas sumažėjo, o išgyvenamumas pagerėjo [21].…”

“…Išplitęs ar recidyvavęs vulvos ir makšties vėžys taip pat laikomas indikacija šiai operacijai [7,11,14,17,20,30]. Diskutuojama dėl dubens eksenteracijos pasirinkimo esant endometro ar kiaušidžių vėžiui, nes šios lokalizacijos onkoprocesai turi tendenciją greitai metastazuoti iš dubens ertmės ir turi gerą jautrumą chemoterapijai [14,33].…”